We invite you to learn more about Iomab-B and Actimab-A.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted radiotherapies for unmet patient needs. Our lead candidate, Iomab-B (I-131 apamistamab) has been studied in over 400 patients, including the positive pivotal Phase 3 SIERRA trial for bone marrow transplant (BMT) conditioning, meeting the primary endpoint of durable Complete Remission (CR) of 6-months with high statistical significance (p<0.0001). Iomab-B enabled an unprecedented 100% access to BMT, significantly improved Event-Free Survival (Hazard Ratio=0.22,p<0.0001), and doubled 1-year and median overall survival. Actimab-A (lintuzumab-Ac225), our second most advanced candidate, has been studied in around 150 patients with Acute Myeloid Leukemia targeting CD33 with mutation agnostic radiation, including in combination with CLAG-M and venetoclax. Actinium has entered into a CRADA with the NCI to develop Actimab-A as a single agent or combination with chemotherapy, targeted agents, or immunotherapy in Phase 1, 2, or 3 trials. Our over 200 patents and leading technology have enabled partnerships with Astellas and LG Chem to further develop novel targeted radiotherapy agents.
Brands: Iomab-B (Phase 3 Complete) for relapsed/refractory AML and BMT
Iomab-ACT (Phase 1/2) for CAR-T, Cell & Gene Therapy
Actimab + CLAG - M (Phase 1 Complete) for AML
Actimab-A + Venetoclax (Phase 1/2) for AML